Sign up
Pharma Capital

Dimerix Ltd's Kathy Harrison discusses positive outcomes from Phase II clinical trial

Kathy Harrison, chief executive for Dimerix, speaks with Proactive Investors.


View full DXB profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.